Close mobile menu×
Close mobile menu

Daniel E. Freedberg, MD, MS

Board Certifications: 
Gastroenterology, Internal Medicine
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Gastroenterology
  • Internal Medicine

Clinical Expertise

  • Digestive System Disorder
  • Gastroenterology
  • Gastrointestinal Disease
  • GERD (Gastroesophageal Reflux Disease)

Education & Training

  • MD, 2008 Harvard Medical School
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

About Daniel Freedberg

Dr. Freedberg graduated from Harvard Medical School and completed his residency and fellowship training at Columbia University. He received a Master's degree in biostatistics from Columbia's Mailman School of Public Health. Dr. Freedberg's research focuses on the use of acid suppression medications, Clostridium difficile infection, and the gastrointestinal microbiome. Current projects include studies of how acid suppression medications alter the colonic microbiome and of how alterations in the gastrointestinal flora predispose patients to Clostridium difficile and other infections during periods of critical illness. His research is funded by the National Institutes of Health and the American Gastroenterological Association.

Academic Titles

  • Assistant Professor Medicine and Epidemiology

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

Research

I am a clinical and translational investigator focused on enteric infections and the gastrointestinal microbiome in the setting of critical illness. I have experience in molecular laboratory research, clinical training as a physician, a dual appointment in Medicine and Epidemiology, and am the recipient of several grants supporting ICU-based human subjects research focused around enteric colonization in the ICU. With funding from the NIH, the American Gastroenterological Association (AGA), and the Department of Defense, I have built large ICU patient cohorts containing longitudinal clinical data, serial rectal swabs, whole stools, and other bio-samples. These data have allowed us to interrogate the dynamic changes that take place within the gastrointestinal microbiome during critical illness and to ask how these changes may impact risk for ICU-acquired infections. Our preliminary studies show that colonizing enteric organisms such as vancomycin-resistant Enterococcus (VRE) are important determinants of patients’ subsequent risk for infection. We have also found that colonizing enteric organisms can change health outcomes for patients who share the same hospital environment, even if these neighboring patients are not themselves colonized. The normal native microbiota resists colonization with VRE, C. difficile, and similar multidrug-resistant or antibiotic-associated organisms, and a major focus of our current work is how to augment enteric colonization resistance in the face of ICU antibiotics.

Grants

PREBIOTIC INULIN TO LIMIT ANTIMICROBIAL RESISTANT INFECTIONS DURING CRITICAL ILLNESS: A PHASE II CLINICAL TRIAL (Federal Gov)

Jul 1 2019 - Jun 30 2023

OTSUKA-COLUMBIA CENTER FOR CLINICAL EPIDEMIOLOGY & HEALTH OUTCOMES RESEARCH (Private)

Nov 1 2019 - Oct 31 2022

LOSS OF GASTROINTESTINAL COLONIZATION RESISTANCE AND ANTIBIOTIC-RESISTANT INFECTIONS IN THE LCU (Federal Gov)

Feb 17 2017 - Dec 31 2020

AMULTI-SITE, RANDOMIZED, DOUBLEBLIND, MULTI-ARM HISTORICAL CONTROL, COMPARATIVE TRIAL OF THE SAFETY AND EFFICACY OF HYDROXYCHLOROQUINE, AND THE COMBINATION OF HYDROXYCHLOROQUINE AND FAMOTIDINE FOR TH (Federal Gov)

Apr 15 2020 - Sep 30 2020

DIETARY FIBER TO PREVENT LOSS OF GASTROINTESTINAL COLONIZATION RESISTANCE AND PATHOGEN COLONIZATION IN THE INTENSIVE CARE UNIT (Private)

May 29 2018 - May 28 2019

CLINICAL AND GUT MICROBIOME FACTORS ASSOCIATED WITH ICU-ACQUIRED INFECTIONS (Private)

Jul 1 2015 - Jun 30 2018

CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

Sep 30 2006 - Jun 30 2016

CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

Sep 30 2006 - Jun 30 2016

Selected Publications

  • Wang Y, Schluger A, Li J, Gomez-Simmonds A. Salmasian H, Freedberg D. Does addition of intravenous metronidazole to oral vancomycin improve outcomes in clostridioides difficile infection? Clin Infect Dis. 2019 pii: ciz1115. doi: 10.1093/cid/ciz1115. PMID: 31714955

  • Freedberg DE, Zhou MJ, Cohen ME, Annavajhala MK, Khan S, Moscoso DI, Brooks C, Whittier S, Chong DH, Uhlemann AC, Abrams JA. Pathogen colonization of the gastrointestinal microbiome at intensive care unit admission and risk for subsequent death or infection. Intensive Care Med. 2018; 44(8):1203-1211. PMID: 29936583

  • Seeley JJ, Baker RG, Mohamed G, Bruns T, Hayden MS, Deshmukh SD, Freedberg DE, Ghosh S. Induction of innate immune memory via microRNA targeting of chromatin remodelling factors. Nature. 2018; 559(7712):114-119. PMID: 29950719